ZAI LAB LIMITED Payments to Acquire Short-term Investments
ZAI LAB LIMITED (ZLAB) reported Payments to Acquire Short-term Investments of $10.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-02-26
- ZAI LAB LIMITED payments to acquire short-term investments for the quarter ending 2024-12-31 was $330.00M.
- ZAI LAB LIMITED payments to acquire short-term investments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED payments to acquire short-term investments for the quarter ending 2024-06-30 was $0.00.
- ZAI LAB LIMITED payments to acquire short-term investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED payments to acquire short-term investments for fiscal 2025 was $10.00M, a 96.97% decline from fiscal 2024.
- ZAI LAB LIMITED payments to acquire short-term investments for fiscal 2024 was $330.00M, a 146.27% increase from fiscal 2023.
- ZAI LAB LIMITED payments to acquire short-term investments for fiscal 2023 was $134.00M, a 48.52% decline from fiscal 2022.
- ZAI LAB LIMITED payments to acquire short-term investments for fiscal 2022 was $260.27M, a 41.51% decline from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.00M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $330.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $330.00M derived: sum of 2 quarters · filed 2026-02-26 | $330.00M derived: sum of 3 quarters · filed 2026-02-26 | $330.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $34.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $34.00M derived: sum of 3 quarters · filed 2026-02-26 | $34.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.00M derived: sum of 2 quarters · filed 2026-02-26 | $34.00M derived: sum of 3 quarters · filed 2026-02-26 | $134.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $34.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $34.00M derived: sum of 2 quarters · filed 2024-11-12 | $134.00M 10-Q · filed 2024-11-12 | $134.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $100.00M 10-Q · filed 2024-08-06 | $100.00M derived: sum of 3 quarters · filed 2025-02-27 | $100.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $100.00M 10-Q · filed 2024-05-08 | $100.00M derived: sum of 2 quarters · filed 2025-02-27 | $100.00M derived: sum of 3 quarters · filed 2025-02-27 | $240.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $140.00M derived: sum of 3 quarters · filed 2025-02-27 | $260.27M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $140.00M derived: sum of 2 quarters · filed 2023-11-07 | $260.27M 10-Q · filed 2023-11-07 | $535.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $140.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $260.27M 10-Q · filed 2023-08-07 | $535.27M derived: sum of 3 quarters · filed 2024-02-27 | $705.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $120.27M 10-Q · filed 2023-05-09 | $395.27M derived: sum of 2 quarters · filed 2024-02-27 | $565.27M derived: sum of 3 quarters · filed 2024-02-27 | $565.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $275.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $445.00M derived: sum of 2 quarters · filed 2024-02-27 | $445.00M derived: sum of 3 quarters · filed 2024-02-27 | $445.00M 10-K · filed 2024-02-27 |
| 2021-09-30 | $170.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $170.00M derived: sum of 2 quarters · filed 2022-11-09 | $170.00M 10-Q · filed 2022-11-09 | $369.49M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $199.49M derived: sum of 3 quarters · filed 2023-03-01 | $744.16M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $199.49M derived: sum of 2 quarters · filed 2023-03-01 | $744.16M derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | $199.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $744.16M derived: sum of 2 quarters · filed 2023-03-01 | $949.16M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $544.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $749.68M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $205.00M 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $26.04M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $76.04M derived: sum of 2 quarters · filed 2022-03-01 | $277.64M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $50.00M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $251.60M 6-K · filed 2020-01-21 | ||
| 2019-06-30 | $201.60M 6-K · filed 2020-09-11 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $200.35M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $200.35M 6-K · filed 2020-01-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |